{"id":"NCT01054885","sponsor":"GlaxoSmithKline","briefTitle":"Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","officialTitle":"A 24-Week Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components Delivered Once Daily (AM) Via a Novel Dry Powder Inhaler Compared With Placebo in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-19","primaryCompletion":"2011-02-01","completion":"2011-02-08","firstPosted":"2010-01-22","resultsPosted":"2013-08-15","lastUpdate":"2018-01-24"},"enrollment":1226,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"FF Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"FF/GW642444 Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"GW642444 Inhalation Powder","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Fluticasone Furoate Inhalation Powder","type":"EXPERIMENTAL"},{"label":"FF Inhalation Pwdr","type":"EXPERIMENTAL"},{"label":"Fluticasone Furoate/GW642444 Inhalation Powder","type":"EXPERIMENTAL"},{"label":"FF/GW642444 Inhalation Pwdr","type":"EXPERIMENTAL"},{"label":"GW642444 Inhalation Powder","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)","primaryOutcome":{"measure":"Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours (h) Post-dose at Day 168","timeFrame":"Baseline (BL) to Day 168","effectByArm":[{"arm":"Placebo","deltaMin":-0.012,"sd":0.0189},{"arm":"FF 100 µg OD","deltaMin":0.034,"sd":0.0187},{"arm":"FF 200 µg OD","deltaMin":0.029,"sd":0.0185},{"arm":"VI 25 µg OD","deltaMin":0.173,"sd":0.0184},{"arm":"FF/VI 100/25 µg OD","deltaMin":0.202,"sd":0.019},{"arm":"FF/VI 200/25 µg OD","deltaMin":0.197,"sd":0.0184}],"pValues":[{"comp":"OG000 vs OG001","p":"0.085"},{"comp":"OG000 vs OG002","p":"0.123"},{"comp":"OG000 vs OG003","p":"<0.001"},{"comp":"OG000 vs OG004","p":"<0.001"},{"comp":"OG000 vs OG005","p":"<0.001"},{"comp":"OG001 vs OG004","p":"<0.001"},{"comp":"OG002 vs OG005","p":"<0.001"},{"comp":"OG003 vs OG004","p":"0.274"},{"comp":"OG003 vs OG005","p":"0.357"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":24},"locations":{"siteCount":149,"countries":["United States","Argentina","Czechia","Germany","Japan","Poland","Romania","Russia","Ukraine"]},"refs":{"pmids":["23332861","40536286","24314123"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":10,"n":205},"commonTop":["Nasopharyngitis","Headache","Upper respiratory tract infection","Oral candidiasis","Oropharyngeal candidiasis"]}}